Daiken MedicalDAIKEN MEDICAL CO.,LTD7775東証スタンダード精密機器FY ending Mar 2026, non-consolidated, J-GAAP
Out of every ¥100 of sales, about ¥12 is left as operating profit. Revenue changed +3.4% from the prior year, operating profit -15.5%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 9.7% | 0.78× | 7.6% | 1.70× | 12.9% |
| 2023 | 7.8% | 0.83× | 6.5% | 1.69× | 10.9% |
| 2024 | 10.1% | 0.89× | 9.0% | 1.62× | 14.6% |
| 2025 | 11.0% | 0.90× | 9.9% | 1.53× | 15.2% |
| 2026 | 9.0% | 0.91× | 8.2% | 1.48× | 12.1% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 8,540 | 9,137 | 9,750 | 9,952 | 10,291 |
| Cost of revenue | 4,856 | 5,607 | 5,768 | 5,855 | 6,339 |
| Gross profit | 3,684 | 3,530 | 3,982 | 4,097 | 3,952 |
| SG&A | 2,533 | 2,476 | 2,539 | 2,585 | 2,674 |
| Operating income | 1,151 | 1,054 | 1,443 | 1,512 | 1,278 |
| Pretax income | 1,151 | 1,025 | 1,436 | 1,508 | 1,246 |
| Income tax | 320 | 313 | 448 | 411 | 323 |
| Net income attributable to owners | 831 | 712 | 989 | 1,098 | 923 |
| Operating margin | 13.5% | 11.5% | 14.8% | 15.2% | 12.4% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥2.52B | ¥2.52B | ¥2.74B | ¥3B | ¥2.78B |
| Total assets | ¥10.9B | ¥11B | ¥11B | ¥11.2B | ¥11.4B |
| Net assets | ¥6.45B | ¥6.6B | ¥7.02B | ¥7.52B | ¥7.78B |
| Share capital | ¥495.9M | ¥495.9M | ¥495.9M | ¥495.9M | ¥495.9M |
| Property, plant and equipment | ¥4.12B | ¥4.07B | ¥3.99B | ¥3.93B | ¥4.04B |
| Intangible assets excluding goodwill | ¥15.1M | ¥9.4M | ¥13.5M | ¥12.9M | ¥22.6M |
| Current assets | ¥6.57B | ¥6.64B | ¥6.73B | ¥6.99B | ¥7.03B |
| Current liabilities | ¥3.15B | ¥3.37B | ¥3.34B | ¥2.83B | ¥2.72B |
| Short-term borrowings | ¥1B | ¥1B | ¥1.08B | ¥720M | ¥920M |
| Long-term borrowings | ¥1.28B | ¥1.01B | ¥623.4M | ¥818.4M | ¥840M |
| Total liabilities | ¥4.47B | ¥4.42B | ¥3.98B | ¥3.67B | ¥3.59B |
| Equity attributable to owners of parent | ¥6.44B | ¥6.58B | ¥6.99B | ¥7.48B | ¥7.75B |
| Retained earnings | ¥7.37B | ¥7.51B | ¥7.92B | ¥8.41B | ¥8.68B |
| Treasury stock | -¥1.83B | -¥1.83B | -¥1.83B | -¥1.83B | -¥1.83B |
EDINET (FSA Japan)
有価証券報告書－第58期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第57期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第56期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第55期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第54期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第53期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 47 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.